Navigation Links
Zactima Receives Fast Track Designation By The FDA

ZACTIMA a product of AstraZeneca has been granted fast track designation by the US Food and Drug Administration (FDA). The drug also received the orphan drug designation // recently for treatment of anaplastic, medullary, follicular, locally advanced and metastatic medullary thyroid cancer. Following the approval, investigation of the drug in the treatment of medullary thyroid carcinoma is expected to accelerate further.

Medullary thyroid cancer accounts for 5 to 10% of all thyroid cancers. Surgery, nuclear medicine (treatment with radioactive iodine), hormonal manipulation, external beam radiotherapy (direction of radiation to kill cancer cells from outside the body) and chemotherapy represent some of the available treatment options.

Presently, there is no satisfactory chemotherapy regimen or other treatment modality for the cure of advanced thyroid cancer. Only those drugs, used for the treatment of severe diseases for which there is an unfulfilled medical need would be granted fast-track status by the FDA.

The fast track review by the FDA would be of immense help in the development of the drug and regulation of the submission process. The pharmaceutical company is currently involved in Phase II clinical trials of the drug, directed against metastatic or locally advanced medullary thyroid cancer.

The compound is believed to play a major role in the inhibition of the growth and spread of the thyroid cancer by participating in vital cell signalling pathways. Vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EFGR) participate in the inhibition pathway while REarranged during Transfection (RET) tyrosine kinases can accelerate the growth of the same.

If the treatment is found to be successful, then we might soon have a new treatment modality for the treatment of medullary thyroid cancer.


'"/>




Page: 1

Related medicine news :

1. Fifth US Patient Receives Artificial Heart
2. Northfield Labs Receives FDA Comments
3. British MPs Say Prostate Cancer Receives Low Priority in the NHS
4. Abbott Receives CE Mark Certification
5. East London Receives World Class New Private Hospital Facility
6. Brinda Karat Receives Legal Notice over Ramdev Issue
7. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
8. Medtronic’s Insulin Pump Receives Regulatory Approva
9. Aurobindo Receives Approval from USFDA for anti-AIDS drug
10. Sunscreen Blocking UVA Radiation Receives Federal Approval
11. Eddie Thompson Receives Advanced Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2017)... UK (PRWEB) , ... June 27, 2017 , ... ... clinical study is whether they can trust the sponsor to pay them correctly and ... that sponsors and CROs establish payment strategies that encourage sites to work on their ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... solution for many of the health care industry’s hospitals and provider groups, has ... financing portal for select customers. Parasail Health is a San Francisco health-finance startup ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on the success of ... the sixth state to pass legislation which ensures that children can possess and ... joins the states of Alabama, Arizona, Florida, Utah and Washington who have also ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... assistance and personal financial planning services to residents of southern New Hampshire, is ... event that promises to fight hunger and homelessness in the region. , New ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... Therapix Biosciences Ltd. (Nasdaq: TRPX), a ... development of cannabinoid-based drugs, today announced that the ... three upcoming scientific and investor conferences in June: ... ... Wednesday, June 7 ...
(Date:5/26/2017)... , May 25, 2017  In response to the ... , Direct Relief is working with Pfizer to make ... at no cost to community health centers, free and ... nationwide. "Pfizer has a long-standing commitment ... and ensuring patient safety through educational activities," said ...
(Date:5/22/2017)... COTTAGE, N.Y. , May 22, 2017 /PRNewswire/ ... antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of a ... plain English, the results of a clinical study ... one year treatment with Gene-Eden-VIR/Novirin in individuals suffering ... important to note that there are no other ...
Breaking Medicine Technology: